{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-069318","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.070276+00:00","generated_at":"2026-06-01T06:16:13.776076+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Shareholders approve all proposals at annual meeting including 5.2M share increase to equity plan","bullets":["All 8 director nominees elected, e.g., Dawn Svoronos 61.5M For vs 4.5M Against; broker non-votes 2.6M.","Say-on-pay advisory vote approved: 64.0M For, 2.0M Against, 0.01M abstain.","Equity plan amendments approved to increase share reserve by 5,200,000 common shares: 63.1M For, 2.8M Against.","KPMG LLP appointed as independent auditor for 2024: 66.7M For, 1.8M Withheld.","Auditor remuneration authority approved: 65.7M For, 0.39M Against, 0.01M Abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-069318","json":"https://secwatch.observer/filing/0000950170-24-069318.json","markdown":"https://secwatch.observer/filing/0000950170-24-069318.md","text":"https://secwatch.observer/filing/0000950170-24-069318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024069318/0000950170-24-069318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024069318/xene-20240604.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:16:13.776076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}